Search results
Showing 226 to 240 of 866 results for score
Prosthetic intervertebral disc replacement in the cervical spine (IPG341)
Evidence-based recommendations on prosthetic intervertebral disc replacement in the cervical spine. This involves removing the damaged disc and inserting an artificial disc in its place.
View recommendations for IPG341Show all sections
Sections for IPG341
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.
View recommendations for TA217Show all sections
Evidence-based recommendations on AposHealth for knee osteoarthritis.
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)
Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.
Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.
Discontinued Reference number: GID-TA10271
Filgotinib for treating moderately to severely active ulcerative colitis (TA792)
Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.
Clostridioides difficile infection: antimicrobial prescribing (NG199)
This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.
Topotecan for the treatment of relapsed small-cell lung cancer (TA184)
Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.
View recommendations for TA184Show all sections
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)
Summary of the evidence on delafloxacin for community-acquired pneumonia in adults
LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29)
NICE has developed a medtech innovation briefing (MIB) on LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands
Evidence-based recommendations on autologous blood injection for tendinopathy. This involves supplying the tendon with growth factors that start the healing process.
View recommendations for IPG438Show all sections
Sections for IPG438
This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.